Immatics (NASDAQ:IMTX) Short Interest Up 5.3% in October

Immatics (NASDAQ:IMTX) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 10,020,000 shares, a growth of 5.3% from the September 30th total of 9,520,000 shares. Based on an average daily volume of 487,400 shares, the short-interest ratio is currently 20.6 days.

Immatics Trading Down 1.4 %

IMTX opened at $9.10 on Friday. Immatics has a 12-month low of $7.15 and a 12-month high of $13.77. The firm has a 50 day moving average of $10.84 and a two-hundred day moving average of $11.34. The firm has a market capitalization of $1.09 billion, a PE ratio of -10.22 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. The firm had revenue of $20.19 million for the quarter, compared to analyst estimates of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. As a group, analysts predict that Immatics will post -0.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IMTX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th. Piper Sandler initiated coverage on Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 price target for the company.

Institutional Trading of Immatics

A number of hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC lifted its holdings in Immatics by 76.5% in the second quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock valued at $93,961,000 after acquiring an additional 3,503,750 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Immatics by 10.4% in the 1st quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock valued at $67,720,000 after purchasing an additional 604,545 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after buying an additional 891,191 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Immatics during the first quarter valued at $18,392,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in Immatics in the second quarter valued at $13,392,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.